Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer

Introduction. Enzalutamide and abiraterone are used for treatment of metastatic castration resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized control trials.Objective. This pharmacoeconomic evaluation compared enzalutamide and abiraterone used prior to chemothera...

Full description

Bibliographic Details
Main Authors: N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
Format: Article
Language:Russian
Published: ABV-press 2017-10-01
Series:Onkourologiâ
Subjects:
Online Access:https://oncourology.abvpress.ru/oncur/article/view/716